Home/Filings/4/0000950170-23-044413
4//SEC Filing

Ignelzi Troy A. 4

Accession 0000950170-23-044413

CIK 0001771917other

Filed

Aug 23, 8:00 PM ET

Accepted

Aug 24, 4:49 PM ET

Size

13.7 KB

Accession

0000950170-23-044413

Insider Transaction Report

Form 4
Period: 2023-08-22
Ignelzi Troy A.
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    2023-08-22$173.64/sh80$13,89131,907 total
  • Exercise/Conversion

    Common Stock

    2023-08-22$9.20/sh+1,500$13,80031,987 total
  • Sale

    Common Stock

    2023-08-22$174.88/sh855$149,52231,052 total
  • Sale

    Common Stock

    2023-08-22$176.60/sh60$10,59630,487 total
  • Sale

    Common Stock

    2023-08-22$175.59/sh505$88,67330,547 total
  • Exercise/Conversion

    Option (right to buy)

    2023-08-221,50093,226 total
    Exercise: $9.20Exp: 2029-03-21Common Stock (1,500 underlying)
Footnotes (6)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.31 to $174.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.32 to $175.31, inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.32 to $176.30, inclusive.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.59 to $176.61, inclusive.
  • [F6]This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.

Documents

1 file

Issuer

Karuna Therapeutics, Inc.

CIK 0001771917

Entity typeother

Related Parties

1
  • filerCIK 0001579829

Filing Metadata

Form type
4
Filed
Aug 23, 8:00 PM ET
Accepted
Aug 24, 4:49 PM ET
Size
13.7 KB